文献速递消化系统肿瘤

BRAF突变晚期结直肠癌不良结局研究:2530例随机临床试验患者分析

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
PubMed 文献 · Ann Oncol · 2017-01-01

基于三项随机试验中2530例晚期结直肠癌患者数据,231例(9.1%)为BRAF突变。BRAF突变独立预示更差生存;一线奥沙利铂/氟尿嘧啶治疗的疾病控制率和无进展生存与野生型无显著差异,但一线进展后生存显著缩短,且接受二线治疗比例更低。

要点

  • BRAF突变晚期结直肠癌患者一线化疗的疾病控制率与无进展生存与野生型无显著差异。
  • 一线进展后生存显著缩短(4.2 vs 9.2个月,校正HR=1.69,P<0.001)。
  • BRAF突变患者接受二线治疗比例更低(33% vs 51%,P<0.001),但二线结局无显著劣于野生型。

核心结论

  • BRAF突变晚期结直肠癌独立预示显著更差预后,但化疗在各治疗线均提供有意义的结局改善。
  • 一线进展后生存显著更差,需警惕确保一线进展后适当给予治疗。

研究设计与样本

  • 分析三项随机临床试验中仅接受化疗的2530例晚期结直肠癌患者个体数据。
  • 终点包括无进展生存、缓解率、疾病控制率、进展后生存和总生存。
  • 治疗包括一线奥沙利铂/氟尿嘧啶和二线伊立替康,临床医生不知晓BRAF状态。

主要发现

  • 231例(9.1%)为BRAF突变肿瘤。
  • 一线奥沙利铂/氟尿嘧啶:BRAF突变 vs 野生型疾病控制率59.2% vs 72%(校正OR=0.76,P=0.24),无进展生存5.7 vs 6.3个月(校正HR=1.14,P=0.26)。
  • 一线进展后生存:BRAF突变 vs 野生型4.2 vs 9.2个月(校正HR=1.69,P<0.001)。
  • 接受二线治疗比例:BRAF突变33% vs 野生型51%(P<0.001);二线缓解率校正OR=0.56(P=0.45),无进展生存校正HR=1.01(P=0.93)。
  • BRAF突变群体内异质性:24.3%患者一线无进展生存和进展后生存均>6个月(总生存24.0个月);36.5%患者一线化疗期间及之后快速进展,总生存4.7个月。

临床怎么用

  • BRAF突变晚期结直肠癌患者一线化疗的疾病控制率和无进展生存与野生型相似。
  • 一线进展后生存显著更差,需警惕确保一线进展后适当给予治疗。
  • BRAF突变患者接受二线治疗比例更低,但二线结局未显著劣于野生型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To improve strategies for the treatment of BRAF-mutant advanced colorectal cancer (aCRC) patients, we examined individual data from patients treated with chemotherapy alone in three randomised trials to identify points on the treatment pathway where outcomes differ from BRAF wild-types. PATIENTS AND METHODS: 2530 aCRC patients were assessed from three randomised trials. End-points were progression-free survival, response rate, disease control rate, post-progression survival (P-PS) and overall survival. Treatments included first-line oxaliplatin/fluorouracil (OxFU) and second-line irinotecan. Clinicians were unaware of BRAF-status. RESULTS: 231 patients (9.1%) had BRAF-mutant tumours. BRAF-mutation conferred significantly worse survival independent of associated clinicopathological factors known to be prognostic. Compared with wild-type, BRAF-mutant patients treated with first-line OxFU had similar DCR (59.2% versus 72%; adjusted OR = 0.76, P = 0.24) and PFS (5.7 versus 6.3 months; adjusted HR = 1.14, P = 0.26). Following progression on first-line chemotherapy, BRAF-mutant patients had a markedly shorter P-PS (4.2 versus 9.2 months, adjusted HR = 1.69, P < 0.001). Fewer BRAF-mutant patients received second-line treatment (33% versus 51%, P < 0.001), but BRAF-mutation was not associated with inferior second-line outcomes (RR adjusted OR = 0.56, P = 0.45; PFS adjusted HR = 1.01, P = 0.93). Significant clinical heterogeneity within the BRAF-mutant population was observed: a proportion (24.3%) had good first-line PFS and P-PS (both >6 months; OS = 24.0 months); however, 36.5% progressed rapidly through first-line chemotherapy and thereafter, with OS = 4.7 months. CONCLUSIONS: BRAF-mutant aCRC confers a markedly worse prognosis independent of associated clinicopathological features. Chemotherapy provides meaningful improvements in outcome throughout treatment lines. Post-progression survival is markedly worse and vigilance is required to ensure appropriate delivery of treatment after first-line progression.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Seligmann JF, Fisher D, Smith CG, et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol. 2017. PMID: 27993800. doi:10.1093/annonc/mdw645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。